| Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1 Q Zeng, W Hong, YH Tan Biochemical and biophysical research communications 244 (2), 421-427, 1998 | 274 | 1998 |
| CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases YHC Tan, S Krishnaswamy, S Nandi, R Kanteti, S Vora, K Onel, R Hasina, ... PloS one 5 (1), e8972, 2010 | 119 | 2010 |
| Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy KI Zhou, B Peterson, A Serritella, J Thomas, N Reizine, S Moya, C Tan, ... Clinical Cancer Research 26 (24), 6453-6463, 2020 | 109 | 2020 |
| Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non–small-cell lung cancer YC Wang, RK Lin, YH Tan, JT Chen, CY Chen, YC Wang Journal of Clinical Oncology 23 (1), 154-164, 2005 | 90 | 2005 |
| Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations PKS Chan, C Zhang, JS Park, KK Smith‐McCune, JM Palefsky, ... International journal of cancer 132 (11), 2528-2536, 2013 | 79 | 2013 |
| The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target BD Ferguson, R Liu, CE Rolle, YHC Tan, V Krasnoperov, R Kanteti, ... PloS one 8 (7), e67668, 2013 | 72 | 2013 |
| OA08. 03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis A Desai, T Karrison, B Rose, Y Tan, B Hill, E Pemberton, C Straus, ... Journal of Thoracic Oncology 13 (10), S339, 2018 | 68 | 2018 |
| A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer YA Tang, WL Wen, JW Chang, TT Wei, YHC Tan, S Salunke, CT Chen, ... PloS one 5 (9), e12417, 2010 | 65 | 2010 |
| A pan-cancer organoid platform for precision medicine BM Larsen, M Kannan, LF Langer, BD Leibowitz, A Bentaieb, A Cancino, ... Cell reports 36 (4), 2021 | 63 | 2021 |
| Accentuation of production of human interferon by metabolic inhibitors M Ho, YH Tan, JA Armstrong Proceedings of the Society for Experimental Biology and Medicine 139 (1 …, 1972 | 55 | 1972 |
| Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer I Kawada, R Hasina, FE Lennon, VP Bindokas, P Usatyuk, YHC Tan, ... Cancer biology & therapy 14 (7), 679-691, 2013 | 45 | 2013 |
| Hierarchical decomposition for betweenness centrality measure of complex networks Y Li, W Li, Y Tan, F Liu, Y Cao, KY Lee Scientific Reports 7 (1), 46491, 2017 | 43 | 2017 |
| OA13. 02 Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis H Kindler, T Karrison, YHC Tan, B Rose, M Ahmad, C Straus, R Sargis, ... Journal of Thoracic Oncology 12 (1), S293-S294, 2017 | 42 | 2017 |
| Novel 2‐step synthetic indole compound 1, 1, 3‐tri (3‐indolyl) cyclohexane inhibits cancer cell growth in lung cancer cells and xenograft models CH Lee, CF Yao, SM Huang, S Ko, YH Tan, GJ Lee‐Chen, YC Wang Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 42 | 2008 |
| An E3 ubiquitin ligase: c‐Cbl: A new therapeutic target of lung cancer FY Lo, YHC Tan, HC Cheng, R Salgia, YC Wang Cancer 117 (23), 5344-5350, 2011 | 38 | 2011 |
| Differential expression of RON in small and non–small cell lung cancers R Kanteti, S Krishnaswamy, D Catenacci, YHC Tan, E EL‐Hashani, ... Genes, Chromosomes and Cancer 51 (9), 841-851, 2012 | 36 | 2012 |
| Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune … CC Foster, MA Couey, SE Kochanny, A Khattri, RK Acharya, YHC Tan, ... Cancer 127 (24), 4565-4573, 2021 | 34 | 2021 |
| Tramadol regulates proliferation, migration and invasion via PTEN/PI3K/AKT signaling in lung adenocarcinoma cells. M Xia, JH Tong, NN Ji, ML Duan, YH Tan, JG Xu European Review for Medical & Pharmacological Sciences 20 (12), 2016 | 34 | 2016 |
| Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). A Desai, T Karrison, B Rose, E Pemberton, B Hill, CM Straus, YHC Tan, ... Journal of Clinical Oncology 36 (15_suppl), 8565-8565, 2018 | 33 | 2018 |
| Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute … J Vigneswaran, YHC Tan, SD Murgu, BM Won, KA Patton, VM Villaflor, ... Oncotarget 7 (14), 18876, 2016 | 31 | 2016 |
